Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the ...

after receiving neoadjuvant Keytruda plus platinum-based chemotherapy. Global recruitment in INTerpath-009 has begun, and the first patients have started enrolling in Canada. Also Read ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...